Newswise — In American women, breast cancer is the second most common cancer and the second leading cause of cancer death. Using data, algorithms and lab experimentation, a biomedical engineer at Washington University in St. Louis is studying breast cancer at the most basic level – the cells – to look for clues about how the cancerous cells metastasize.
Kristen Naegle, assistant professor of biomedical engineering in the School of Engineering & Applied Science, applied her unique computational skills to look at the HER2 gene. HER2-positive breast cancers are aggressive and spread faster than other types. Researchers have found that too much protein is made from the HER2 gene — called overexpression — in 20 percent of all breast cancers, making HER2 a valuable target for potential personalized treatment methods for this type of breast cancer.
To determine why HER2-positive cancers are more aggressive, Naegle analyzed measurements from a previous study that isolated signaling molecules in a HER2-overexpressing breast cell line and a normal breast cell.
“We use mathematical approaches to find similarities in the data,” Naegle said. “For this dataset, we looked at how signaling molecules are most related to each other in the normal cells, compared to how they are related to each other in the HER2-overexpressing cells. We looked for relationships that are drastically different in the two cell types to understand how signaling is altered. Despite the fact that individual molecules are highly similar to each other across cell types, we found that small changes in signaling dynamics led to very large changes in the relationships uncovered between groups of signaling molecules.”
One of these big changes they found involves a protein that regulates how cells are connected.
“One of the things that decreases metastatic behavior is that the cells stick tightly together through cell-cell junctions,” Naegle said. “That told us that if there are signaling alterations happening at the cell junctions, then maybe that’s why these cells are more metastatic.”
Naegle and members of her lab tested the hypothesis that interactions with this cell junction protein were altered according to the differences in the signaling relationships they saw from their analysis. They found that interactions with the cell junction protein were very different between the two cell types, and the interaction dynamics matched the dynamics of the signaling that uncovered the relationship.
“This is exciting, because it’s been proposed that testing for interactions in a cancer biopsy may be a better predictor of how a cancer will respond to a treatment,” Naegle said. “Given that some HER2-positive breast cancer patients don’t respond to HER2 therapy, maybe this protein interaction could help us identify patients who will respond well to therapy and those who will not gain additional benefits.”
Additionally, with Venktesh Shirure, a former research scientists in biomedical engineering, the team conducted a series of experiments to test whether cell junctions were altered in the conditions that correspond with the most aggressive cell type. Their experiments revealed that the cell junctions in with high HER2 expression break down and become “leaky” in response to the growth factor, which may be related to how HER2-postive cancers metastasize.
“This study shows that by using a different mathematical interpretation of the data, even a decade after its first publication, we can still find new nuggets of information hidden in these high-throughput, systems-level measurements of early signaling dynamics and identify novel, unknown findings,” Naegle said.
“My lab believes that disease is a context shift, so what we should fundamentally understand is how context shapes cell decisions and then understanding disease becomes relatively trivial,” Naegle said. “It’s a bottom-up approach where we look to understand the basic mechanisms of the interactions in the cell to find the outcomes. There still remains a wealth of hypotheses from this analysis that may continue to help us understand how HER2 drives metastasis.”
The School of Engineering & Applied Science at Washington University in St. Louis focuses intellectual efforts through a new convergence paradigm and builds on strengths, particularly as applied to medicine and health, energy and environment, entrepreneurship and security. With 94 tenured/tenure-track and 28 additional full-time faculty, 1,200 undergraduate students, 1,200 graduate students and 20,000 alumni, we are working to leverage our partnerships with academic and industry partners — across disciplines and across the world — to contribute to solving the greatest global challenges of the 21st century.
MEDIA CONTACTRegister for reporter access to contact details